Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Not yet recruiting 3Unknown 2Recruiting 2Active not recruiting 2Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1

Interventions

Trastuzumab 25Carboplatin 20Paclitaxel 19pertuzumab 18pyrotinib 17Cyclophosphamide 17Capecitabine 16Docetaxel 15trastuzumab deruxtecan 14Radiotherapy 13Drug Therapy 13Standard of Care 12Letrozole 12Fulvestrant 12dalpiciclib 11pembrolizumab 9exemestane 9Epirubicin 9Anastrozole 9sacituzumab govitecan 8palbociclib 8eribulin 8Specimen Handling 8Doxorubicin 7130-nm albumin-bound paclitaxel 7toripalimab 6abemaciclib 6Tamoxifen 6Neoadjuvant Therapy 6Magnetic Resonance Spectroscopy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × ARX788 × Breast × Clear all
NCT06224673 2026-05-01

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

University of California, San Francisco

Phase 2 Not yet recruiting
36 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06663748 2024-10-29

ARX788 in HER2-positive Metastatic Breast Cancer Patients

Henan Cancer Hospital

Phase 2 Not yet recruiting
44 enrolled
Breast

Breast Neoplasms

NCT06578286 2024-08-29

ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

Fudan University

Phase 2 Not yet recruiting
44 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡